ASH 2025 | What are the key findings from the 12-month primary endpoint analysis of the ROP-ET phase III study?
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
ASH 2025 | What are the key findings from the 12-month primary endpoint analysis of the ROP-ET phase III study?
-
ナレーター：
-
著者：
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the MPN Hub was pleased to speak with Jean-Jacques Kiladjian, Université Paris Cité, Paris, FR. We asked, What are the key findings from the 12-month primary endpoint analysis of the ROP-ET phase III study?
In this interview, Kiladjian first provided an overview of the phase III ROP-ET (NCT06514807) study design and key patient eligibility criteria. He then discussed the primary endpoint results, highlighting that the ROP-ET study met the primary endpoint – a composite durable hematologic and clinical response after 12 months. Finally, Kiladjian explored the safety profile of ropeginterferon alfa-2b observed in the study.
This educational resource is independently supported by AOP Health. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
Hosted on Acast. See acast.com/privacy for more information.